logo
Florida officials warn about risks of raw milk after 21 people sickened

Florida officials warn about risks of raw milk after 21 people sickened

Yahoo3 days ago
The Florida Department of Health is warning about the risks of drinking raw, unpasteurized milk after 21 people, including six children under the age of 10, were sickened by E. coli and campylobacter bacteria linked to raw milk from the same farm. Seven people have been hospitalized, and two have developed severe complications.
"Sanitation practices in this farm are of particular concern due to the number of cases," the department said in a news release. Officials did not identify the farm, but indicated its products were available in Northeast and Central Florida. CBS News has reached out to the health department for more information.
Although it is illegal to sell raw milk for human consumption in Florida, it can be sold in the state if it's labeled as a pet food. Raw milk has been promoted by online wellness influencers and raw food advocates, boosting sales in recent years, but public health officials say it can be risky.
The Food and Drug Administration and the Centers for Disease Control and Prevention say raw milk can carry life-threatening bacteria, such as E. coli, campylobacter, listeria or salmonella.
These can cause symptoms including diarrhea, vomiting and stomach cramps. Severe cases can result in a condition called hemolytic uremic syndrome, or HUS, which can lead to kidney failure.
Since 1987, 143 outbreaks have been linked to raw milk or raw milk products, some involving miscarriages, stillbirths, kidney failure and even deaths, according to the FDA.
Pasteurization — a process of heating the milk — kills these bacteria. Pasteurization is required by federal law for any milk sold across state lines. Some individual states also restrict or ban the sale of raw milk, but others allow it.
In an interview with CBS News Miami earlier this year, Mark McAfee, founder of one of the world's largest raw milk producers and head of an advocacy group called the Raw Milk Institute, claimed raw milk offers health benefits such as bioactives that boost the immune system. McAfee sells his raw milk legally in California, where no state law prohibits its sale.
But the CDC says such claims are unfounded. "Pasteurized milk offers the same nutritional benefits without the risks of raw milk consumption," the agency says.
The Florida Department of Health noted in its statement that "many people consume raw milk safely." But it also advised, "Floridians should be aware of potential risks associated with consumption, which may vary depending on the source of milk.The producer's handling of raw milk and milking procedures are vital in prevention of contamination."
How safe is our Social Security safety net?
Texas House votes to arrest lawmakers who fled state to stop redistricting vote
What is "most-favored nation" drug pricing and how does it work?
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mindologue Crowned 'Best Mental Health App in the USA 2025'
Mindologue Crowned 'Best Mental Health App in the USA 2025'

Associated Press

time28 minutes ago

  • Associated Press

Mindologue Crowned 'Best Mental Health App in the USA 2025'

Co-Founder and CEO - Diana Renard Mindologue is the award-winning mental-wellness app that turns creativity into clarity. Snap or sketch a doodle and our AI decodes color, shape, and stroke to reveal what your emotions are really saying. It securely remembers your drawings, chats, and mood logs to build a living profile, then delivers personalized voice-guided meditations, context-aware support chats, and stunning visual breath-work effects, all in your pocket, anytime you need calm or insight. Miami, Florida - August 7, 2025 - In a digital-first world searching for deeper emotional connection, Mindologue has emerged as the clear front-runner, earning the title ' Best Mental Health App in the USA 2025 '. Co-founded by visionary Diana Renard and former space-engineer and entrepreneur, turned CTO Fabrice Colozzi, Mindologue intertwines clinically grounded art-therapy principles with cutting-edge AI to deliver real-time emotional insight, bespoke meditations, and an elegant path to self-healing. A Market Hungry for Better Help The global mental-health-apps market is expected to surge from US $7.5 billion in 2025 to nearly US $24 billion by 2032 (18 % CAGR), with North America already commanding almost half of that revenue Fortune Business Insights. Against this backdrop of explosive growth, and an unprecedented demand for accessible, stigma-free care, Mindologue's creativity-driven approach is rewriting the rulebook. From Personal Struggle to Global Solution Mindologue was born when Diana Renard confronted her own post-crisis recovery. ' I'm not a licensed therapist; I'm a visionary building tools for a new generation of self-healers, ' she explains. Frustrated by one-size-fits-all mood trackers and chatbots, Diana imagined an experience that felt as intuitive as sketching in a notebook yet as insightful as a seasoned counselor. Enter Fabrice Colozzi, whose background in orbital systems engineering and AI research transformed that vision into reality. The duo prototyped an algorithm that analyzes color, stroke pressure, balance, and symbolism in user drawings, mapping those data points to evidence-based emotional markers. The result: a personalized 'emotional fingerprint' delivered in seconds, no questionnaires, no judgment, just honest insight. What Makes Mindologue Unmatched Voices Behind the Victory ' Technology should not replace therapy; it should lower the threshold to begin healing. Mindologue gives people a safe, creative space to explore what they're feeling. Our AI helps connect the dots. ' - Diana Renard, Co-Founder & CEO ' We engineered Mindologue like a spacecraft: robust, adaptive, and built to perform under pressure, because mental well-being deserves the same precision as any critical system. ' - Fabrice Colozzi, Co-Founder & CTO Clinicians have taken notice too. Art therapist Dr. Elena Morozova, who beta-tested the platform with trauma survivors, notes: ' Patients who were reluctant to verbalize pain found their drawings 'heard' by the app. That alone broke down walls that months of talk therapy couldn't. ' Impact Beyond the Individual According to the CDC, 1 in 5 adults in the United States live with a diagnosable mental health condition, yet fewer than half receive formal treatment. Mindologue fills that accessibility gap: Experience the Revolution Media & Partnerships: [email protected] Media Contact Company Name: Mindologue LLC Contact Person: Sarah Cohen Email: Send Email Phone: 7862851360 Address:Biscayne Blvd City: MIAMI State: FL Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Mindologue Crowned 'Best Mental Health App in the USA 2025"

Eli Lilly's oral GLP-1RA hits endpoints, but trails Novo's Wegovy in weight loss
Eli Lilly's oral GLP-1RA hits endpoints, but trails Novo's Wegovy in weight loss

Yahoo

time41 minutes ago

  • Yahoo

Eli Lilly's oral GLP-1RA hits endpoints, but trails Novo's Wegovy in weight loss

Eli Lilly's oral glucagon-like peptide receptor agonist (GLP-1RA) has met the primary and secondary endpoints in a Phase III trial, though its weight loss efficacy lags Novo Nordisk's oral drug. In the Phase III ATTAIN-1 trial (NCT05869903), all three doses of once-daily orforglipron delivered statistically and clinically meaningful weight loss of up to 12.4% in the high dose cohort (36mg) after 72 weeks of dosing. In addition, the cohort saw that more than half the patients (59.6%) achieved weight loss reductions of over 10% and 39.6% achieved more than a 15% drop in body weight. A 7.8% weight loss was reported in the low dose (6mg) cohort while in the medium dose (12mg), there was a weight loss of 9.3%. A 0.9% weight loss was seen in the placebo cohort. The safety profile of orforglipron remained consistent with marketed GLP-1RA's and most commonly reported adverse events (AEs) were gastrointestinal and generally mild-to-moderate in severity. Discontinuation rates in the low, medium and high doses were 21.9%, 22.5% and 24.4% respectively, compared to 29.9% with placebo. In April 2025, Lilly said that the Phase III ACHIEVE-1 trial (NCT05971940) of orforglipron in type 2 diabetes (T2D) had met its primary endpoint, reducing A1C levels by an average of 1.3% to 1.6% from a baseline of 8% after 40 weeks. Novo likely to beat Lilly to market In early 2025, Novo Nordisk said it submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) after its oral 25mg semaglutide demonstrated 13.6% weight loss compared to 2.2% in the placebo cohort after a 64-week dosing period in the OASIS4 trial (NCT05035095). While this comparison of data does not come from a head-to-head in a study, it is notable that Novo Nordisk's drug had a higher weight loss, with investors asking about the comparison to Novo Nordisk's data in the Q2 earnings call on 7 August; however, a Lilly executive stated it is difficult to compare the two trials. Novo Nordisk expects a decision from the FDA in Q4 2025 for the oral semaglutide, which will be marketed as Wegovy, similar to its subcutaneous version of the drug approved for weight loss. Oral semaglutide is already available on the market for patients with T2D, under the name Rybelsus, first gaining FDA approval in 2019. Lilly also confirmed in the 7 August announcement that it will file for review of the oral GLP-1RA with global regulators by the end of 2025. Based on Lilly's April announcement, submission for the drug in T2D is anticipated in 2026. As a result of Novo Nordisk's earlier filing, if approved, it will hold a first-to-market advantage in the oral GLP-1RA obesity field, but Jasper Morley, pharma analyst for GlobalData, said that this will not play out in the long term. Morley shared: 'Novo Nordisk's oral semaglutide for obesity and Eli Lilly's orforglipron calcium's approvals would represent the first oral GLP-1RAs for obesity. 'While both products are expected to launch by 2026, orforglipron calcium is expected to reach blockbuster status first, in 2027, and generate $14.1bn in 2031. Meanwhile, oral semaglutide is expected to reach blockbuster status by 2029 and eventually generate $2.6bn in 2031.' Eli Lilly and Novo Nordisk rivalry intensifies Lilly revealed the Phase III ATTAIN-1 data on the same day as the company's Q2 financials, which showed sales for its subcutaneous GLP-1RA for weight loss, Zepbound (tirzepatide), were $3.38bn, up 172% compared with Q2 2024. Its T2D version of tirzepatide, Mounjaro, also saw its sales rise by 68% compared to the same period in 2024. Meanwhile, in its H1 and Q2 financials announcement made on 6 August, Novo Nordisk confirmed that sales of its subcutaneous semaglutide products, Wegovy for weight loss and Ozempic for T2D, had increased 16% in H1, compared to a 26% growth for the drugs in H1 2024. Investors will be keeping an eye on the two companies as they remain the dominant players on the GLP-1RA stage, but there are smaller biotechs and big pharma companies, including Pfizer, that are also hoping to gain a portion of the GLP-1RA market as they develop their pipeline assets. "Eli Lilly's oral GLP-1RA hits endpoints, but trails Novo's Wegovy in weight loss" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Water Tower Research Publishes Initiation of Coverage Report on Tian Ruixiang Holdings Limited, 'From Traditional Insurance Broker to Tech-Based Health Insurance Innovator'
Water Tower Research Publishes Initiation of Coverage Report on Tian Ruixiang Holdings Limited, 'From Traditional Insurance Broker to Tech-Based Health Insurance Innovator'

Yahoo

timean hour ago

  • Yahoo

Water Tower Research Publishes Initiation of Coverage Report on Tian Ruixiang Holdings Limited, 'From Traditional Insurance Broker to Tech-Based Health Insurance Innovator'

Water Tower Research ( has published an Initiation of Coverage Report on Tian Ruixiang Holdings Limited (NASDAQ: TIRX) titled, 'From Traditional Insurance Broker to Tech- Based Health Insurance Innovator'. The report can be accessed here. ST. PETERSBURG, FL, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Water Tower Research ( has published an Initiation of Coverage Report on Tian Ruixiang Holdings Limited (NASDAQ: TIRX) titled, 'From Traditional Insurance Broker to Tech- Based Health Insurance Innovator'. The report can be accessed here. Access to China's growing health insurance market. On June 30, 2025, Chinese insurance broker Tian Ruixiang Holdings Limited completed the acquisition of Ucare, which describes itself as the only cloud-based healthcare value assessment and insurance risk control SaaS platform in China, for total all-stock consideration of $150 million. Ucare's wealth of AI-driven analytics strongly positions TIRX in China's commercial health insurance market, a segment of China's insurance market in which the company has been historically under- represented historically, and which is expected to expand from ~$126 billion today to $280 billion by 2030. Scalable, high-margin SaaS drives reliable revenue in value-based payment & risk analytics. Ucare's cloud-native, multi-tenant platform combined with a network of >4,000 hospital relations, scales with minimal incremental cost, generating gross margins above 90% and recurring subscription-based revenue that complements TIRX's brokerage commission income. This underpins more stable and higher-quality top-line growth as adoption broadens across Ucare's large hospital network. Regulatory and cross-border tailwinds. China's aging demographics, policy reforms to encourage greater healthcare access and affordability, accelerating healthcare digitization adoption (with the domestic healthcare IT market projected to reach ~US$35 billion by 2030 at a CAGR of ~15.6%), present significant tailwinds for TIRX's uniquely enhanced AI- brokerage business model to unlock significant growth potential. Additionally, TIRX has the opportunity to supplement growth with the implementation of its strategy to expand beyond Mainland China recently begun with its move into Hong Kong. Overall, our model projects 35% revenue CAGR to FY28 on a pro forma basis. Valuation. Based on our projections, TIRX's combination with Ucare significantly enhances its revenue growth prospects. Relative to these prospects, TIRX's valuations are below most of our selected comps on both a Price and EV basis. About Water Tower Research Water Tower Research is modernizing investor engagement through research-driven communications. Sound investment research begins with good information. At WTR, we help companies and investors connect by creating expert information flow and strategies that are the foundation of a successful modern investor relations platform. Our analysts and capital markets professionals bring decades of unrivaled Wall Street experience and insight to a new digital world of investor communications and engagement. Our research and investor content is distributed across traditional research aggregators like Bloomberg, FactSet, etc., proprietary direct distribution lists, social media, search engines, and our website. As a result, every institutional and retail investor has equal access to our high-quality company research. Our mission is to help companies take control of their IR program and proactively reach investors while bringing investors a consistent flow of quality information to help them understand our clients' businesses, industries, and the investment opportunities they present. CONTACT: Name: Water Tower Research LLC Email: research@ Job Title: WTR Investor EngagementError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store